Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2007-03-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if erlotinib will improve disease at doses that
produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.